Novartis has terminated the mid-stage study of Fabhalta in lupus but will pursue late-stage studies in atypical haemolytic uraemic syndrome and generalized myasthenia gravis. Results from these studies are anticipated later this year and next year.

CAR-T cell therapy, traditionally used for blood cancers, is being explored for autoimmune diseases such as lupus, multiple sclerosis, and scleroderma. Experts believe this innovative approach could revolutionize treatment for these challenging conditions.

Recent research highlights immunosuppressant-refractory multifaceted immune dysregulations in systemic lupus erythematosus. This study provides insights into the complex immune mechanisms underlying the disease, which may inform future therapeutic strategies.

A case report highlights that primary erythromelalgia linked to an SCN9A variant can present with skin manifestations similar to systemic lupus erythematosus. This finding underscores the need for careful differential diagnosis in patients exhibiting these symptoms.

Biogen's litifilimab shows promising results in treating cutaneous lupus, achieving clear or almost clear skin in patients within one year in a mid-stage study. Phase 3 data for systemic lupus is anticipated by year-end, potentially advancing Biogen's position in the lupus market.